N-terminal pro-brain natriuretic peptide - A promising biomarker for the diagnosis of left ventricular hypertrophy in hypertensive women

Archives of Cardiovascular Diseases

Volumn 101, Issue 5, 2008, Pages 307-315

  Mouly Bertin, Carine ^a   Bissery, Alvine ^b,c,d   Milon, Hugues ^c,e   Dzudie, Anastase ^a   Rabilloud, Muriel ^b,c,d   Bricca, Giampiero ^a,c,e   Vincent, Madeleine ^a,c,e   Lantelme, Pierre ^a,c,e  

^a CROIX ROUSSE HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d LABORATOIRE DE BIOMÉTRIE ET BIOLOGIE EVOLUTIVE   (France)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATINE;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 49749127260     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2008.04.007     Document Type: Article

References (43)

1. Schillaci G, Verdecchia P, Porceliati C, et al. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000;35(2):580-6.
2. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322(22):1561-6.
3. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25(6):1105-87.
4. Spranger CB, Ries AJ, Berge CA, et al. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med 2004;117(1):14-8.
5. Cuspidi C, Meani S, Vaterio C, et al. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 2006;24(8):1671-7.
6. Mukoyama M, Nakao K, Saito Y, et al. Human brain natriuretic peptide, a novel cardiac hormone. Lancet 1990;335(8692): 801-2.
7. Kohno M, Horio T, Yokokawa K, et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 1992;92(1):29-34.
8. Yamamoto K, Burnett Jr JC, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 1996;28(6):988-94.
9. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996;28(1): 22-30.
10. Cheung BM. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol 1997;24(12):966-8.
11. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002;288(10):1252-9.
12. Nakamura M, Tanaka F, Yonezawa S, et al. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 2003;16(12):1025-9.
13. Conen D, Pfisterer M, Martina B. Substantial intraindividual variability of BNP concentrations in patients with hypertension. J Hum Hypertens 2006;20(6):387-91.
14. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004;341(1-2):41-8.
15. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21(6):1011-1053.
16. O'Brien E, Mee F, Atkins N, O'Malley K. The quest for better validation: a critical comparison of the AAMI and BHS validation protocols for ambulatory blood pressure measurement systems. Biomed Instrum Technol 1992;26(5):395-9.
17. Collinson PO, Barnes SC, Gaze DC, et al. Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers. Eur J Heart Fail 2004;6(3):365-8.
18. Casale PN, Devereux RB, Alonso DR, et al. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation 1987;75(3):565-72.
19. Lantelme P, Bouchayer D, Gayet C, et al. Influence of a rapid change of left ventricular dimensions on the echocardiographic measurement of left ventricular mass by the Penn convention. J Hypertens 1999;17(9):1323-8.
20. de Simone G, Devereux RB, Daniels SR, et al. Effect of growth on variability of left ventricular mass: assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995;25(5):1056-62.
21. Rossvoll O, Hatle LK. Pulmonary venous flow velocities recorded by transthoracic Doppler ultrasound: relation to left ventricular diastolic pressures. J Am Coll Cardiol 1993;21(7):1687-96.
22. Nagueh SF, Middleton KJ, Kopeten HA, et al. Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997;30(6):1527-33.
23. Garcia MJ, Thomas JD, Klein AL. New Doppler echocardiographic applications for the study of diastolic function. J Am Coll Cardiol 1998;32(4):865-75.
24. Nagueh SF, Lakkis NM, Middleton KJ, et al. Doppler estimation of left ventricular filling pressures in patients with hypertrophic cardiomyopathy. Circulation 1999;99(2):254-61.
25. Khouri SJ, Maly GT, Suh DD, Walsh TE. A practical approach to the echocardiographic evaluation of diastolic function. J Am Soc Echocardiogr 2004;17(3):290-7.
26. Alonzo TA, Pepe MS. Distribution-free ROC analysis using binary regression techniques. Biostatistics 2002;3(3):421-32.
27. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3(1):32-5.
28. Mancia G, Carugo S, Grassi G, et al. Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension 2002;39(3):744-9.
29. Bettencourt P, Ferreira A, Sousa T, et al. Brain natriuretic peptide as a marker of cardiac involvement in hypertension. Int J Cardiol 1999;69(2):169-77.
30. Uusimaa P, Tokota H, Ytitato A, et al. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 2004;97(2):251-6.
31. Hildebrandt P, Boesen M, Olsen M, et al. N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 2004;6(3):313-7.
32. Tschope C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005;26(21):2277-84.
33. Conen D, Zeller A, Pfisterer M, Martina B. Usefulness of B-type natriuretic peptide and C-reactive protein in predicting the presence or absence of left ventricular hypertrophy in patients with systemic hypertension. Am J Cardiol 2006;97(2):249-52.
34. Belluardo P, Cataliotti A, Bonaiuto L, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2006;291(4):H1529-35.
35. Goetze JP, Mogelvang R, Maage L, et al. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006;27(24):3004-10.
36. Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study. J Am Coll Cardiol 2006;48(9):1808-12.
37. Chang AY, Abdullah SM, Jain T, et al. Associations among androgens, estrogens, and natriuretic peptides in young women: observations from the Dallas Heart Study. J Am Coll Cardiol 2007;49(1):109-16.
38. Luchner A, Brockel U, Muscholl M, et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 2002;53(3):720-7.
39. Johnston N, Jernberg T. Lindahl B, et al. Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 2004;37(3):210-6.
40. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006;47(1):91-7.
41. Julien J, Tranche C, Souchet T. Left ventricutar hypertrophy in hypertensive patients. Epidemiology and prognosis. Arch Mal Coeur Vaiss 2004;97(3):221-7.
42. McKie PM, Rodeheffer RJ, Cataliotti A. et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47(5):874-80.
43. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350(7):655-63.